BioCryst is rolling out a print magazine to help rare disease patients on Orladeyo find information.
May 11, 2023 01:06 PM EDT
Pharma
Marketing

BioCryst de­buts print mag­a­zine for hered­i­tary an­gioede­ma pa­tients tak­ing Or­ladeyo

Beth Snyder Bulik

Senior Editor

BioCryst Phar­ma­ceu­ti­cals is go­ing old school with a print mag­a­zine sent in the mail for peo­ple tak­ing its hered­i­tary an­gioede­ma (HAE) drug, Or­ladeyo. In its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times